Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) - Net Assets
Based on the latest financial reports, Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) has net assets worth CN¥3.25 Billion CNY (≈ $475.28 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.49 Billion ≈ $949.62 Million USD) and total liabilities (CN¥3.24 Billion ≈ $474.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688131 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.25 Billion |
| % of Total Assets | 50.05% |
| Annual Growth Rate | 77.41% |
| 5-Year Change | 413.38% |
| 10-Year Change | 16481.09% |
| Growth Volatility | 89.63 |
Shanghai Haoyuan Chemexpress Co. Ltd. A - Net Assets Trend (2013–2025)
This chart illustrates how Shanghai Haoyuan Chemexpress Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See 688131 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Haoyuan Chemexpress Co. Ltd. A (2013–2025)
The table below shows the annual net assets of Shanghai Haoyuan Chemexpress Co. Ltd. A from 2013 to 2025. For live valuation and market cap data, see 688131 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.43 Billion ≈ $1.38 Billion |
+224.62% |
| 2024-12-31 | CN¥2.90 Billion ≈ $424.98 Million |
+14.96% |
| 2023-12-31 | CN¥2.53 Billion ≈ $369.67 Million |
+8.33% |
| 2022-12-31 | CN¥2.33 Billion ≈ $341.24 Million |
+26.98% |
| 2021-12-31 | CN¥1.84 Billion ≈ $268.73 Million |
+247.94% |
| 2020-12-31 | CN¥527.81 Million ≈ $77.24 Million |
+32.04% |
| 2019-12-31 | CN¥399.73 Million ≈ $58.49 Million |
+125.01% |
| 2018-12-31 | CN¥177.65 Million ≈ $26.00 Million |
+54.83% |
| 2017-12-31 | CN¥114.74 Million ≈ $16.79 Million |
+101.79% |
| 2016-12-31 | CN¥56.86 Million ≈ $8.32 Million |
+74.13% |
| 2015-12-31 | CN¥32.65 Million ≈ $4.78 Million |
-1.36% |
| 2014-12-31 | CN¥33.10 Million ≈ $4.84 Million |
+241.37% |
| 2013-12-31 | CN¥9.70 Million ≈ $1.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Haoyuan Chemexpress Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12232.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥999.00 Million | 31.88% |
| Other Comprehensive Income | CN¥3.11 Billion | 99.32% |
| Total Equity | CN¥3.13 Billion | 100.00% |
Shanghai Haoyuan Chemexpress Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Haoyuan Chemexpress Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Air France-KLM SA
PA:AF
|
$2.68 Billion |
|
Fibra Danhos
MX:DANHOS13
|
$2.68 Billion |
|
Seadrill Limited
NYSE:SDRL
|
$2.68 Billion |
|
China Merchants Securities Co. Ltd
F:195H
|
$2.68 Billion |
|
Delek Logistics Partners LP
NYSE:DKL
|
$2.68 Billion |
|
Worthington Industries Inc
NYSE:WOR
|
$2.68 Billion |
|
SASA Polyester Sanayi AS
IS:SASA
|
$2.68 Billion |
|
Harley-Davidson Inc
NYSE:HOG
|
$2.68 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Haoyuan Chemexpress Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,877,877,144 to 3,133,594,000, a change of 255,716,856 (8.9%).
- Net income of 247,768,619 contributed positively to equity growth.
- Dividend payments of 78,024,135 reduced retained earnings.
- Other comprehensive income increased equity by 2,890,580,546.
- Other factors decreased equity by 2,804,608,174.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥247.77 Million | +7.91% |
| Dividends Paid | CN¥78.02 Million | -2.49% |
| Other Comprehensive Income | CN¥2.89 Billion | +92.24% |
| Other Changes | CN¥-2.80 Billion | -89.5% |
| Total Change | CN¥- | 8.89% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Haoyuan Chemexpress Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 65.98x to 5.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.31 | CN¥86.37 | x |
| 2014-12-31 | CN¥22.06 | CN¥86.37 | x |
| 2015-12-31 | CN¥1.64 | CN¥86.37 | x |
| 2016-12-31 | CN¥2.64 | CN¥86.37 | x |
| 2017-12-31 | CN¥0.61 | CN¥86.37 | x |
| 2018-12-31 | CN¥1.41 | CN¥86.37 | x |
| 2019-12-31 | CN¥2.70 | CN¥86.37 | x |
| 2020-12-31 | CN¥3.44 | CN¥86.37 | x |
| 2021-12-31 | CN¥10.22 | CN¥86.37 | x |
| 2022-12-31 | CN¥11.38 | CN¥86.37 | x |
| 2023-12-31 | CN¥12.01 | CN¥86.37 | x |
| 2024-12-31 | CN¥13.70 | CN¥86.37 | x |
| 2025-12-31 | CN¥14.80 | CN¥86.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Haoyuan Chemexpress Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.91%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.64%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 2.01x
- Recent ROE (7.91%) is below the historical average (15.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 23.97% | 3.96% | 1.70x | 3.56x | CN¥1.35 Million |
| 2014 | 9.52% | 4.70% | 1.17x | 1.73x | CN¥-158.95K |
| 2015 | 26.14% | 9.28% | 1.23x | 2.28x | CN¥5.27 Million |
| 2016 | 32.19% | 15.39% | 0.75x | 2.79x | CN¥12.42 Million |
| 2017 | 13.08% | 8.63% | 0.91x | 1.67x | CN¥3.53 Million |
| 2018 | 10.37% | 6.13% | 0.99x | 1.71x | CN¥648.67K |
| 2019 | 18.37% | 17.95% | 0.75x | 1.36x | CN¥33.46 Million |
| 2020 | 24.33% | 20.22% | 0.74x | 1.62x | CN¥75.65 Million |
| 2021 | 10.48% | 19.70% | 0.41x | 1.31x | CN¥8.75 Million |
| 2022 | 8.35% | 14.26% | 0.38x | 1.55x | CN¥-38.35 Million |
| 2023 | 5.08% | 6.78% | 0.45x | 1.67x | CN¥-123.46 Million |
| 2024 | 7.00% | 8.88% | 0.41x | 1.91x | CN¥-86.20 Million |
| 2025 | 7.91% | 8.64% | 0.46x | 2.01x | CN¥-65.59 Million |
Industry Comparison
This section compares Shanghai Haoyuan Chemexpress Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) | CN¥3.25 Billion | 23.97% | 1.00x | $2.68 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.